newsfilter
← Latest News
Business Wire·

Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Enrollment completed in PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis; revising guidance of topline data to first half 2025 PALIZADE Phase 2b clinical trial of zetomipzomib in